Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial-Reference-Cited by-同舟云学术

Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial

Published:2022-05 Issue:3 Volume:3 Page:100239
ISSN:2666-6758
Container-title:The Innovation
language:en
Short-container-title:The Innovation

Author:

Lu Zhihao,Zhang Yanqiao,Fan Qingxia,Pan Yueyin,Jiang Da,Lu Ping,Zhang Jingdong,Yuan Xianglin,Feng Jifeng,Yang Shujun,Yue Wenbin,Zhao Lin,Xu Yunhua,Luo Jinhua,Shen Lin

Publisher

Elsevier BV

Subject

Multidisciplinary

Reference48 articles.

1. Global Cancer Statistics 2018: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA. Cancer J. Clin.,2018

2. Incidence and mortality of esophagus cancer in China, 2008-2012;He;Chin. J. Cancer Res.,2019

3. Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer;Qin;World J. Gastroenterol.,2009

4. A phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer;Cao;Jpn. J. Clin. Oncol.,2009

5. Efficacy and safety of recombinant human lymphotoxin-α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: a randomized, multicenter, open-label, controlled, phase 2b trial;Wang;Cancer,2017

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinoma;Signal Transduction and Targeted Therapy;2024-06-28

2. Meta-analysis of studies on the effectiveness of adding anti-PD1 antibodies to the first-line chemotherapy in advanced esophageal cancer;Malignant tumours;2023-06-21

3. Advances in the Theranostics of Oesophageal Squamous Carcinoma;Advanced Therapeutics;2023-04-16

4. The Molecular Characterization of Genetic Abnormalities in Esophageal Squamous Cell Carcinoma May Foster the Development of Targeted Therapies;Current Oncology;2023-01-03